With respect to Her2 (human epidermal growth factor receptor 2)-targeted therapy, combination of trastuzumab and chemotherapy was the best first-line standard of care for advanced/metastatic HER2-positive cancers patients [22]. This evidence concerns the gene ERBB2 and cancer.